News Center
livzon has won the Sina Finance 2023 Pharmaceutical Industry Golden Qilin Award for "Most Socially Responsible Pharmaceutical Company".
Release time:
2023-12-22
The Sina Finance 2023 Pharmaceutical and Capital Forum was held in Beijing on December 21, where the list of winners for the Sina Finance 2023 Pharmaceutical Industry Golden Unicorn Award was announced. Livzon Pharmaceutical Group was honored as the "Most Socially Responsible Pharmaceutical Company" for its outstanding performance in the field of social responsibility.
The capital market is an important driving force for the development of pharmaceutical companies. The selection of the Sina Finance 2023 Pharmaceutical Industry Golden Unicorn Award focuses on observing the pharmaceutical industry through the lens of the capital market, aiming to recognize the pharmaceutical companies most favored by the capital market and to support the high-quality development of the pharmaceutical industry.
The high-quality development of the pharmaceutical industry requires not only adherence to independent research and innovation but also active fulfillment of corporate social responsibility, demonstrating the commitment of the health industry. In recent years, Livzon Pharmaceutical Group has adhered to a development strategy driven by innovative drugs and high-barrier complex formulations, relying on three national-level R&D platforms: the "National Modernization Engineering Technology Research Center for Traditional Chinese Medicine," the "National Recognized Enterprise Technology Center," and the "National-Local Joint Engineering Center for Long-acting Microspheres," as well as eight provincial-level R&D platforms, establishing a research and innovation system covering various fields including chemical drugs, biological drugs, raw materials, traditional Chinese medicine, and in vitro diagnostics, laying a solid foundation for independent research and innovation.
Livzon Pharmaceutical Group actively practices the ESG strategy, building new momentum for sustainable development. In 2023, Livzon Pharmaceutical Group received the highest global MSCI ESG rating of AAA, becoming the first Chinese company in the global pharmaceutical industry to obtain the highest MSCI ESG AAA rating; it scored 65 points in the S&P ESG rating, ranking among the top 5 global pharmaceutical companies evaluated; in 2023, it received an AA rating in the Wind ESG rating, ranking first among domestic pharmaceutical peers; it was recognized in the top 20 of the 2023 China Pharmaceutical Listed Companies ESG Competitiveness, the top 100 of the 2023 Wind China Listed Companies ESG Best Practices, and received an AAA rating in the CSI Index ESG rating, among many other honors, with the outstanding performance of the group's ESG management work widely recognized by the capital market.
Related Information